Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
1997-5-23
|
pubmed:abstractText |
In a prospective study, plasma concentrations of human calcitonin (hCT) were determined in 1062 consecutive patients with thyroid nodular disease. Basal plasma hCT was above the normal range (>6 pg/mL) in 55 patients and was elevated up to more than 100 pg/mL (range, 127-5459) in 3 of these 55 patients. A pentagastrin-induced rise in hCT up to more than 100 pg/mL was observed in only 1 of 38 patients with a basal concentration of hCT between 5-10 pg/mL, but was found in 10 of 31 patients with basal hCT ranging from 10-100 pg/mL. Histologically, 7 of the 14 patients with either basal or stimulated plasma concentrations of hCT above 100 pg/mL presented C cell hyperplasia, which in one case showed histological transition into a small (diameter, 3 mm) medullary thyroid carcinoma (MTC). Including this patient, MTC was found in 6 of the 12 patients. We conclude that the routine determination of hCT in all patients with thyroid nodular disease should be supplemented by pentagastrin-stimulation when the basal hCT concentration exceeds 10 pg/mL. Patients with basal and/or stimulated plasma CT concentrations of more than 100 pg/mL should be operated on because they run a substantial risk to suffer either MTC or C cell hyperplasia, a potentially precancerous condition. This will increase the chance of a timely diagnosis of MTC and provide the chance of curative surgery.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0021-972X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
82
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1589-93
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:9141554-Calcitonin,
pubmed-meshheading:9141554-Carcinoma, Medullary,
pubmed-meshheading:9141554-Humans,
pubmed-meshheading:9141554-Hyperplasia,
pubmed-meshheading:9141554-Pentagastrin,
pubmed-meshheading:9141554-Prospective Studies,
pubmed-meshheading:9141554-Thyroid Diseases,
pubmed-meshheading:9141554-Thyroid Neoplasms,
pubmed-meshheading:9141554-Thyroid Nodule
|
pubmed:year |
1997
|
pubmed:articleTitle |
Routine measurement of plasma calcitonin in nodular thyroid diseases.
|
pubmed:affiliation |
Department of Internal Medicine III, University of Vienna, and St. Anna Kinderspital, Austria.
|
pubmed:publicationType |
Journal Article
|